Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omicron strain COVID-19 Vaccine (Vero Cell), Inactivated
- Development stage
- Unknown
- Lead developer
- Beijing Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Omicron strain COVID-19 Vaccine (Vero Cell), Inactivated is an inactivated whole-virus vaccine developed by the Beijing Institute of Biological Products (BIBP), a subsidiary of China National Biotec Group (CNBG) and Sinopharm. The vaccine is derived from the SARS-CoV-2 Omicron variant (specifically the BA.1 subvariant, strain HK-OM-P0) cultivated in Vero cells and inactivated with beta-propiolactone. It is formulated with an aluminum hydroxide adjuvant to enhance immunogenicity. The vaccine is designed to prevent COVID-19 caused by the Omicron variant by inducing neutralizing antibodies and cellular immune responses specifically targeting the Spike protein and other structural proteins of the Omicron strain. It has been evaluated in Phase 1/2 and Phase 3 clinical trials as a primary series or booster immunization.
- Other names
- BIBP Inactivated COVID-19 vaccine (Omicron)BIBP Omicron Inactivated COVID-19 vaccineBIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)BIBP-COVID-19 inactivated vaccine (Omicron)Omicron COVID-19 Vaccine (Vero Cell), InactivatedOmicron SARS-CoV-2 vaccineOmicron-strain inactivated COVID-19 vaccine
02
Targets
ACE2 (Angiotensin-converting enzyme 2)RBD (SARS-CoV-2 spike receptor-binding domain)SARS-CoV-2 spike
Beyond the preview
Go deeper on Omicron strain COVID-19 Vaccine (Vero Cell), Inactivated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omicron strain COVID-19 Vaccine (Vero Cell), Inactivated.